Search Result

Results for "

Phosphodiesterase (PDE)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phosphodiesterase (PDE) (174) 5-HT Receptor (1) Adenosine Deaminase (1) Adenosine Receptor (6) Adrenergic Receptor (2) Apoptosis (17) Autophagy (11) Bacterial (4) Beta-secretase (1) Calcium Channel (6) Calmodulin (1) Casein Kinase (2) Cholinesterase (ChE) (1) Dopamine Receptor (1) Drug Metabolite (1) Endogenous Metabolite (12) GABA Receptor (1) Glucocorticoid Receptor (2) GPR35 (1) GSK-3 (2) HDAC (6) Histamine Receptor (3) HIV (4) IKK (2) Influenza Virus (2) Interleukin Related (4) Isotope-Labeled Compounds (4) JAK (1) mAChR (2) Molecular Glues (3) Na+/H+ Exchanger (NHE) (1) NO Synthase (3) Parasite (2) PKA (6) Potassium Channel (1) Sodium Channel (2) TNF Receptor (7) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (44) Cardiovascular Disease (42) Endocrinology (17) Infection (8) Inflammation/Immunology (57) Metabolic Disease (15) Neurological Disease (54)

By Targets:

Phosphodiesterase (PDE) (174)

5-HT Receptor (1)

Adenosine Deaminase (1)

Adenosine Receptor (6)

Adrenergic Receptor (2)

Apoptosis (17)

Autophagy (11)

Bacterial (4)

Beta-secretase (1)

Calcium Channel (6)

Calmodulin (1)

Casein Kinase (2)

Cholinesterase (ChE) (1)

Dopamine Receptor (1)

Drug Metabolite (1)

Endogenous Metabolite (12)

GABA Receptor (1)

Glucocorticoid Receptor (2)

GPR35 (1)

GSK-3 (2)

HDAC (6)

Histamine Receptor (3)

HIV (4)

IKK (2)

Influenza Virus (2)

Interleukin Related (4)

Isotope-Labeled Compounds (4)

JAK (1)

mAChR (2)

Molecular Glues (3)

Na+/H+ Exchanger (NHE) (1)

NO Synthase (3)

Parasite (2)

PKA (6)

Potassium Channel (1)

Sodium Channel (2)

TNF Receptor (7)

Wnt (2)

β-catenin (2)

By Research Areas:

Cancer (44)

Cardiovascular Disease (42)

Endocrinology (17)

Infection (8)

Inflammation/Immunology (57)

Metabolic Disease (15)

Neurological Disease (54)

178

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Phosphodiesterase (PDE)

Cat. No.	Product Name	Target	Research Areas

HY-P2878

Phosphodiesterase PDE	Phosphodiesterase (PDE)	Neurological Disease
Phosphodiesterase (PDE) is an enzyme that can catalyze the hydrolysis of the 3' ring phosphate bond of cyclic nucleotides, and is often used in biochemical research. Phosphodiesterase acts as an important regulator of signal transduction mediated by the second messenger molecules cAMP and cGMP. According to their specificity to cyclic nucleotides, they can also be divided into different types, such as PDE1-PDE11, which also have certain potential in various diseases.

HY-B0312

Dipyridamole 2 Publications Verification	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis.

HY-126137

PDE9-IN-1

Phosphodiesterase (PDE) Neurological Disease

PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC₅₀ of 8.7 nM.
HY-U00427

PDE2/PDE10-IN-1

Phosphodiesterase (PDE) Neurological Disease

PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and PDE10 inhibitor with IC₅₀s of 29 and 480 nM, respectively.
HY-142660

PDE2A-IN-1

Phosphodiesterase (PDE) Neurological Disease

PDE2A-IN-1 is a phosphodiesterase 2A (PDE2A) inhibitor with an IC₅₀ value of 1.3 nM.

PDE9-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE9-IN-1 is a potent, selective, and orally bioavailable **phosphodiesterase-9A (PDE9A) Inhibitor with an IC₅₀** of 8.7 nM.

PDE2/PDE10-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and *PDE10* inhibitor with IC₅₀s of 29 and 480 nM, respectively.

PDE2A-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE2A-IN-1 is a **phosphodiesterase 2A (PDE2A) inhibitor with an IC₅₀** value of 1.3 nM.

HY-119611A

Thioquinapiperifil dihydrochloride KF31327	Phosphodiesterase (PDE)	Endocrinology Metabolic Disease
Thioquinapiperifil dihydrochloride (KF31327), a potent, selective and non-competitive **phosphodiesterase-5 (PDE-5, IC₅₀** of 0.074 nM) inhibitor, is used for sexual enhancement study.

HY-16900

Rolipram 5+ Cited Publications (R,S)-Rolipram; (±)-Rolipram; ZK 62711	Phosphodiesterase (PDE) Bacterial HIV	Neurological Disease Cancer
Rolipram is a selective phosphodiesterases *PDE4* inhibitor with IC₅₀s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-U00254

L791943

Phosphodiesterase (PDE) Neurological Disease

L791943 is a potent, selective Phosphodiesterase-4 (PDE4) inhibitor with an IC₅₀ of 4.2 nM.

L791943	Phosphodiesterase (PDE)	Neurological Disease
L791943 is a potent, selective *Phosphodiesterase-4* (PDE4) inhibitor with an IC₅₀ of 4.2 nM.

HY-109193

Tovinontrine IMR-687	Phosphodiesterase (PDE)	Cardiovascular Disease
Tovinontrine (IMR-687) is a highly potent and selective **phosphodiesterase-9 (PDE9) inhibitor specifically for the treatment of sickle cell disease. IC₅₀*s are 8.19 nM and 9.99 nM for PDE9A1 and PDE*9A2, respectively.

HY-101661

Win 58237	Phosphodiesterase (PDE)	Cardiovascular Disease
Win 58237 is a cyclic nucleotide **phosphodiesterase (PDE) inhibitor, with K_i** of 170 nM for PDE V, possessing vasorelaxant activity.

HY-122942

Moracin M	Phosphodiesterase (PDE) Endogenous Metabolite	Inflammation/Immunology
Moracin M, a phenolic component in the skin of Morus alba Linn., is a potent **phosphodiesterase-4 (PDE4) inhibitor with IC₅₀** values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity.

HY-124768

PDE12-IN-3

Phosphodiesterase (PDE) Infection Inflammation/Immunology

PDE12-IN-3 is a phosphodiesterase 12 (PDE12) inhibitor with a pXC₅₀ of 7.68. Antiviral activity.

PDE12-IN-3	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
PDE12-IN-3 is a phosphodiesterase 12 (PDE12) inhibitor with a pXC₅₀ of 7.68. Antiviral activity.

HY-119611

Thioquinapiperifil KF31327 free base	Phosphodiesterase (PDE)	Endocrinology Metabolic Disease
Thioquinapiperifil (KF31327 free base), a potent, selective and non-competitive **phosphodiesterase-5 (PDE-5, IC₅₀** of 0.074 nM) inhibitor, is used for sexual enhancement study.

HY-W011336

PDE5-IN-7

Phosphodiesterase (PDE) Others

PDE5-IN-7 (compound 8) is a selective phosphodiesterase 5 (PDE 5) inhibitor with an IC₅₀ value of 5 nM, while an IC₅₀ of 300 nM for PDE 1.
HY-101644A

Saterinone hydrochloride

BDF 8634 hydrochloride
Phosphodiesterase (PDE) Cardiovascular Disease

Saterinone hydrochloride is a phosphodiesterase III (PDE III) inhibitor.

PDE5-IN-7	Phosphodiesterase (PDE)	Others
PDE5-IN-7 (compound 8) is a selective phosphodiesterase 5 (PDE 5) inhibitor with an IC₅₀ value of 5 nM, while an IC₅₀ of 300 nM for PDE 1.

Saterinone hydrochloride BDF 8634 hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Saterinone hydrochloride is a phosphodiesterase III (PDE III) inhibitor.

HY-16900A

(R)-(-)-Rolipram 2 Publications Verification (R)-Rolipram; (-)-Rolipram	Phosphodiesterase (PDE)	Neurological Disease
(R)-(-)-Rolipram is the R-enantiomer of Rolipram. Rolipram is a selective inhibitor of phosphodiesterases *PDE4* with IC₅₀ of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-100927

Ro 20-1724 Ro 20-174	Phosphodiesterase (PDE)	Neurological Disease
Ro 20-1724 (Ro 20-174) is a potent inhibitor of cAMP-specific phosphodiesterase *(PDE4/PDE* IV) with a K_i** of 1930 nM. Neuroprotective effect.

HY-12318

IBMX Maximum Cited Publications 25 Publications Verification 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Phosphodiesterase (PDE)	Inflammation/Immunology
IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC₅₀s of 6.5, 26.3 and 31.7 μM for *PDE3, PDE4* and *PDE5*, respectively.

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Endocrinology Cardiovascular Disease
Avanafil (TA-1790) is a potent and selective **phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀** values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.

HY-147990

PDE5-IN-5

Phosphodiesterase (PDE) Cancer

PDE5-IN-5 (Compound 11) is a potent, selective phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 2.0 nM.

PDE5-IN-5	Phosphodiesterase (PDE)	Cancer
PDE5-IN-5 (Compound 11) is a potent, selective **phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀** of 2.0 nM.

HY-A0027

Fenspiride hydrochloride	Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology Endocrinology
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases.

HY-A0027A

Fenspiride	Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases.

HY-B0442S

Vardenafil-d5	Phosphodiesterase (PDE) Endogenous Metabolite	Endocrinology
Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction[1][2].

HY-128358

MR-L2	Phosphodiesterase (PDE)	Neurological Disease
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform **phosphodiesterase-4 (PDE4)*, activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC₅₀* of 1.2 µM.

HY-14550A

PDE10-IN-5

Phosphodiesterase (PDE) Others

PDE10-IN-5 is a phosphodiesterase 10 (PDE 10) inhibitor, can be used for researching certain central nervous system (CNS) disorders.

PDE10-IN-5	Phosphodiesterase (PDE)	Others
PDE10-IN-5 is a phosphodiesterase 10 (PDE 10) inhibitor, can be used for researching certain central nervous system (CNS) disorders.

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Endocrinology Cardiovascular Disease
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective **phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀** values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis.

HY-100326

PDE7-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology Neurological Disease
Pde7-in-3 (example 2) is an inhibitor of the phosphodiesterase *PDE7* with potential analgesic activity. PDE7-IN-3 can be used to study inflammatory, neuropathic, visceral and nociceptive pain.

HY-145583

Mufemilast

Hemay005
Phosphodiesterase (PDE) Others

Mufemilast is a phosphodiesterase 4 (PDE4) inhibitor.

Mufemilast Hemay005	Phosphodiesterase (PDE)	Others
Mufemilast is a **phosphodiesterase 4 (PDE4)** inhibitor.

HY-B0442

Vardenafil 2 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Endocrinology Metabolic Disease Inflammation/Immunology
Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 2 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Endocrinology Metabolic Disease Inflammation/Immunology
Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes^[1]-[6].

HY-112555

PDE7-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE7-IN-2 (compound 2) is a potent PDE7 (phosphodiesterase 7) inhibitor with IC₅₀ value of 2.1 µM. PDE7-IN-2 has the potential for the research of parkinson’s disease.

HY-U00186

K134 OPC33509	Phosphodiesterase (PDE)	Cardiovascular Disease
K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC₅₀s of K134 toward *PDE3A, PDE3B, PDE5, PDE2 and PDE*4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.

HY-B0442C

Vardenafil dihydrochloride	Endogenous Metabolite Phosphodiesterase (PDE)	Endocrinology Metabolic Disease Inflammation/Immunology
Vardenafil dihydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes^-.

HY-A0027AS

Fenspiride-d5	Isotope-Labeled Compounds Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology
Fenspiride-d₅ is the deuterium labeled Fenspiride. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases[1][2][3].

HY-147946

PDE1-IN-4	Phosphodiesterase (PDE) Calcium Channel	Inflammation/Immunology
PDE1-IN-4 (compound 2g) is a potent and selective *PDE1* (phosphodiesterase-1) inhibitor, with IC₅₀ values of 10, 145, and 354 nM for *PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE*1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research.

HY-136350

BRD9500	Phosphodiesterase (PDE)	Cancer
BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC₅₀s of 10 and 27 nM for *PDE3A* and *PDE3B*, respectively. Antitumor activity.

HY-130262

PDE1-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE1-IN-3, compound 4 (WO2019156861), is a selective human **phosphodiesterase 1 (PDE1)** inhibitor. PDE1-IN-3 inhibits PDE4D and PDE6AB with IC₅₀ values of 23.99 μM and 10 μM, respectively.

HY-B0442B

Vardenafil hydrochloride trihydrate 1 Publications Verification	Endogenous Metabolite Phosphodiesterase (PDE)	Endocrinology Metabolic Disease Inflammation/Immunology
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes^[1]-[6].

HY-150060

PDE4-IN-11	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-11 is an inhibitor of phosphodiesterase isoenzyme 4 (PDE4). PDE4-IN-11 displays highly effective bronchodilatory and anti-inflammatory properties, can be used for obstructive or inflammatory airway diseases research.

HY-U00374

Sch59498

Phosphodiesterase (PDE) Neurological Disease

Sch59498 is a potent inhibitor of phosphodiesterase 1c (Pde1c).

Sch59498	Phosphodiesterase (PDE)	Neurological Disease
Sch59498 is a potent inhibitor of **phosphodiesterase 1c (Pde1c)**.

HY-142059

PDE5-IN-4	Phosphodiesterase (PDE)	Metabolic Disease Cardiovascular Disease
PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure.

HY-N3324

Mangostanol (+)-Mangostanol	Phosphodiesterase (PDE)	Others
Mangostanol ((+)-Mangostanol) is a polyoxygenated xanthone mangostanol, which can be isolated from the shell of Garcinia mangostana, and has inhibitory effect on cAMP *phosphodiesterase* (PDE).

HY-101826

ER21355

Phosphodiesterase (PDE) Cancer

ER21355 is an inhibitor of phosphodiesterase 5 (PDE5), used for treatment of prostatic diseases.

ER21355	Phosphodiesterase (PDE)	Cancer
ER21355 is an inhibitor of **phosphodiesterase 5 (PDE5)**, used for treatment of prostatic diseases.

HY-17464

Cilostazol 3 Publications Verification OPC 13013	Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease Cancer
Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM.

HY-147991

PDE5/HDAC-IN-1	Phosphodiesterase (PDE) HDAC Apoptosis	Cancer
PDE5/HDAC-IN-1 (Compound 26) is a potent **phosphodiesterase 5 (PDE5) and HDAC inhibitor with IC₅₀** values of 46.3 nM and 14.5 nM, respectively. PDE5/HDAC-IN-1 induces cell apoptosis and shows anticancer activities.

HY-123743

JNJ-42314415	Phosphodiesterase (PDE)	Neurological Disease
JNJ-42314415 is a centrally active **phosphodiesterase 10A (PDE10A) inhibitor, with K_i** values of 35 nM and 64 nM for human recombinant PDE10A and rPDE10A, respectively.

HY-128349

MT-3014	Phosphodiesterase (PDE)	Neurological Disease
MT-3014 is a potent, highly selective and brain-penetrated phosphodiesterase 10A (PDE 10A) inhibitor, with IC₅₀s of 0.062 nM and 0.09 nM for human PDE 10A and bovine PDE 10A, respectively.

HY-131973

PDE10A-IN-2 hydrochloride	Phosphodiesterase (PDE)	Metabolic Disease Cardiovascular Disease
PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active **phosphodiesterase 10A (PDE10A) inhibitor with an IC₅₀** of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research.

HY-15025A

Sildenafil citrate 5+ Cited Publications UK-92480 citrate	Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial	Cardiovascular Disease Cancer
Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

HY-100615

Revizinone

R80122
Phosphodiesterase (PDE) Cardiovascular Disease

Revizinone is a novel selective phosphodiesterase (PDE) inhibitor with IC50 values on this enzyme to 0.036 microM.

HY-115745

Calmodulin antagonist-1	Calmodulin	Cardiovascular Disease
Calmodulin antagonist-1 (A-5) is a calmodulin (CaM) antagonist. Calmodulin antagonist-1 inhibits calmodulin-activated Ca²⁺-phosphodiesterase (PDE) (IC₅₀=66 μM). Calmodulin antagonist-1 also inhibits trypsin-treated Ca²⁺-PDE (IC₅₀=560 μM) in a competitive fashion with respect to cyclic GMP.

HY-15178

Oglemilast GRC 3886	Phosphodiesterase (PDE)	Inflammation/Immunology
Oglemilast (GRC 3886) is a potent and orally active **phosphodiesterase-4 (PDE4) inhibitor with an IC₅₀** of 0.5 nM for PDE4D3. Oglemilast inhibits pulmonary cell infiltration, including eosinophilia and neutrophilia in vitro and in vivo. Oglemilast has the potential for inflammatory airway diseases.

HY-N2958

Braylin	Phosphodiesterase (PDE)	Inflammation/Immunology
Braylin, a coumarin, is a potent phosphodiesterase-4 (PDE4) inhibitor and is involved in anti-inflammatory and immunomodulation, which may serve as a potential target for the study of immunoinflammatory diseases.

HY-117571

Zatolmilast 2 Publications Verification BPN14770	Phosphodiesterase (PDE)	Neurological Disease
Zatolmilast (BPN14770) is a selective **phosphodiesterase 4D (PDE4D) allosteric inhibitor with IC₅₀*s of 7.8 nM and 7.4 nM for PDE4D7 and PDE*4D3, respectively.

HY-149782

Phosphodiesterase-IN-1	Parasite Phosphodiesterase (PDE)	Infection
Phosphodiesterase-IN-1 (Compound 7) is a phosphodiesterase (PDE) inhibitor with anti-Plasmodium activity. Phosphodiesterase-IN-1 has antiproliferative activity against P. falciparum (strain 3D7) with an IC₅₀ value of 0.64 μM.

HY-12913

AMG 579

Phosphodiesterase (PDE) Neurological Disease

AMG 579 is a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A) with an IC₅₀ of 0.1 nM.

HY-14254

Olprinone Hydrochloride Loprinone Hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC₅₀s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity.

HY-14254A

Olprinone Loprinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC₅₀s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity.

HY-117977

FCPR03	Phosphodiesterase (PDE)	Inflammation/Immunology Neurological Disease
FCPR03 is a potent and selective **phosphodiesterase 4 (PDE4) inhibitor with IC₅₀** values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain, *PDE4B1* and *PDE4D7, respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs* (PDE1-3 and PDE5-11). FCPR03 has anti-inflammatory, neuroprotective and antidepressant-like effects.

HY-U00352

PDE IV-IN-1	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE IV-IN-1 is an inhibitor of phosphodiesterase IV, used for the research of asthma, COPD or other inflammatory diseases.

HY-123210

Lodenafil

Hydroxyhomosildenafil
Phosphodiesterase (PDE) Endocrinology

Lodenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).
HY-111371

PF-05180999

PF-999
Phosphodiesterase (PDE) Neurological Disease

PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC₅₀ of 1.6 nM.

HY-15025

Sildenafil 5+ Cited Publications UK-92480	Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial	Cardiovascular Disease Cancer
Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

HY-W028690

DNMDP 2 Publications Verification	Phosphodiesterase (PDE)	Cancer
DNMDP, a **phosphodiesterase 3A (PDE3A)** inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity.

HY-70069

GSK256066 Trifluoroacetate 1 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology
GSK256066 Trifluoroacetate is a selective and high-affinity **phosphodiesterase 4 (PDE) inhibitor, with an IC₅₀** of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease.

HY-152838

Gemlapodect RO554965	Phosphodiesterase (PDE)	Neurological Disease
Gemlapodect (RO554965) is an inhibitor of **phosphodiesterase 10A (PDE10A)**. Gemlapodect can be used for researching schizophrenia.

HY-12740

Lotamilast

RVT-501; E6005
Phosphodiesterase (PDE) Inflammation/Immunology

Lotamilast (RVT-501; E6005) is a selective phosphodiesterase 4 (PDE4) inhibitor with an IC₅₀ of 2.8 nM.

HY-10469

GSK256066 1 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology
GSK256066 is a selective and high-affinity **phosphodiesterase 4 (PDE4) inhibitor, with an IC₅₀** of 3.2 pM for PDE4B. GSK256066 is developed for the research of chronic obstructive pulmonary disease.

HY-114672

MBCQ	Phosphodiesterase (PDE)	Cardiovascular Disease
MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC₅₀ of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC₅₀s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE.

HY-124775

(S)-C33	Phosphodiesterase (PDE)	Neurological Disease
(S)-C33 is a potent and selective **PDE9 (phosphodiesterase-9) inhibitor, with an IC₅₀** of 11 nM. (S)-C33 can be used for central nervous system diseases and diabetes research.

HY-17464S

Cilostazol-d11	Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease Cancer
Cilostazol-d₁₁ is the deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

HY-17464S1

Cilostazol-d4 OPC-13013-d₄	Isotope-Labeled Compounds Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease Cancer
Cilostazol-d₄ is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

HY-106003

GSK356278	Phosphodiesterase (PDE)	Inflammation/Immunology Neurological Disease
GSK356278 is a potent, selective, orally bioavailable and brain-penetrant inhibitor of **phosphodiesterase 4 (PDE4), with pIC₅₀*s of 8.6, 8.8, and 8.7 for human PDE4A, PDE4B, and PDE*4D, respectively. GSK356278 has anti-inflammatory activity, and exhibits anxiolytic and cognition-enhancing effects.

HY-N1860

3-O-Methylquercetin	Phosphodiesterase (PDE)	Inflammation/Immunology
3-O-Methylquercetin (3-MQ), a main constituent of Rhamnus nakaharai, inhibits total cAMP and cGMP-phosphodiesterase (PDE) of guinea pig trachealis. 3-O-Methylquercetin (3-MQ) exhibits IC₅₀ values ranging from 1.6-86.9 μM for PDE isozymes (PDE1-5).

HY-121037

Eggmanone EGM1	Phosphodiesterase (PDE)	Cancer
Eggmanone (EGM1) is a potent and selective **phosphodiesterase 4 (PDE4) antagonist with an IC₅₀** of 72 nM for PDE4D3. Eggmanone shows approximately 40- to 50-fold selective for PDE4D3 over other PDEs. Eggmanone exerts its Hh-inhibitory effects through selective antagonism of PDE4, leading to protein kinase A activation and subsequent Hh blockade.

HY-135848

N-Methylbenzamide

Phosphodiesterase (PDE) Cancer

N-Methylbenzamide is a potent phosphodiesterase 10A (PDE10A) inhibitor. N-Methylbenzamide has anti-cancer activity.

HY-19102

NSP-805	Phosphodiesterase (PDE)	Cardiovascular Disease
NSP-805 is a potent and selective inhibitor of guinea pig cardiac **phosphodiesterase 3 (PDE3)**, and a cardiotonic agent with vasodilator properties.

HY-121381

Kuraridine	Phosphodiesterase (PDE)	Others
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC₅₀=0.64 μM).

HY-12085

Apremilast 5+ Cited Publications CC-10004	Phosphodiesterase (PDE) Apoptosis TNF Receptor	Inflammation/Immunology
Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM.

HY-136350B

(S)-BRD9500	Others	Cancer
(S)-BRD9500 is the inactive isomer of BRD9500 (HY-136350), and can be used as an experimental control. BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC₅₀s of 10 and 27 nM for *PDE3A* and *PDE3B*, respectively. Antitumor activity.

HY-117605

N-Desmethyl Sildenafil Desmethylsildenafil; UK-103,320	Phosphodiesterase (PDE)	Cardiovascular Disease
N-Desmethyl Sildenafil (Desmethylsildenafil) is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor.

HY-U00136

Win-62005	Phosphodiesterase (PDE)	Cardiovascular Disease
Win-62005 is a cyclic AMP phosphodiesterase III (PDE III) inhibitor with K_is of 25 and 26 nM for rat heart and canine aorta, respectively.

HY-107191

Sildenafil Mesylate	Phosphodiesterase (PDE)	Cancer
Sildenafil Mesylate is an orally active and selective *phosphodiesterase* type 5 (PDE5) inhibitor. Sildenafil Mesylate can be used in studies of erectile dysfunction and cancer.

HY-13927

Acetildenafil	Phosphodiesterase (PDE)	Cancer Cardiovascular Disease
Acetildenafil is a Sildenafil (HY-15025) analogue, a phosphodiesterase 5 (PDE5) inhibitor. Acetildenafil can be isolated from herbal products.

HY-B0809S

Theophylline-d6 1,3-Dimethylxanthine-d₆; Theo-24-d₆	Adenosine Receptor Phosphodiesterase (PDE) Autophagy Endogenous Metabolite	Cancer
Theophylline-d₆ is the deuterium labeled Theophylline. Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.

HY-103493

TAK-915	Phosphodiesterase (PDE)	Neurological Disease
TAK-915 is a potent, selective, brain-penetrant and orally active **phosphodiesterase 2A (PDE2A) inhibitor with an IC₅₀ of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A** than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment.

HY-105349

T-0156	Phosphodiesterase (PDE)	Neurological Disease
T-0156 is a potent and selective **phosphodiesterase type 5 (PDE5)** inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC₅₀=0.23 nM). T-0156 inhibits PDE6 (IC₅₀=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC₅₀>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway.

HY-132821A

Irsenontrine maleate E2027 maleate	Phosphodiesterase (PDE)	Neurological Disease
Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases.

HY-10790

Cilomilast 1 Publications Verification SB-207499	Phosphodiesterase (PDE)	Inflammation/Immunology
Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of **Phosphodiesterase 4 (PDE4), with IC₅₀*s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC₅₀*=74, 65, >100, and 83 µM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD).

HY-117604

THPP-1	Phosphodiesterase (PDE)	Neurological Disease
THPP-1, a SGC chemical probe, is a potent and orally bioavailable **phosphodiesterase 10A (PDE10A) inhibitor, with K_i** values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species.

HY-12085S

Apremilast-d5 CC-10004-d₅	Phosphodiesterase (PDE) TNF Receptor Apoptosis	Inflammation/Immunology
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].

HY-114303

CM-675	Phosphodiesterase (PDE) HDAC	Neurological Disease
CM-675 is a dual **phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC₅₀** values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675 has potential to treat Alzheimer’s disease.

HY-103160A

EHNA hydrochloride 3 Publications Verification	Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus	Cancer Infection Neurological Disease Cardiovascular Disease
EHNA hydrochloride is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC₅₀=4 μM) and adenosine deaminase (ADA). EHNA hydrochloride exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC₅₀:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA hydrochloride play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects.

HY-132821

Irsenontrine E2027	Phosphodiesterase (PDE)	Neurological Disease
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases.

HY-109085

Difamilast 1 Publications Verification OPA-15406	Phosphodiesterase (PDE)	Inflammation/Immunology
Difamilast (OPA-15406) is a topical, selective and nonsteroidal **phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC₅₀**=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD).

HY-19672

Lirimilast BAY 19-8004	Phosphodiesterase (PDE)	Inflammation/Immunology
Lirimilast (BAY 19-8004) is a potent, selective and orally active **phosphodiesterase-4 (PDE4) inhibitor with an IC₅₀** value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties.

HY-N10317

Toddacoumalone	Phosphodiesterase (PDE)	Inflammation/Immunology
Toddacoumalone is a natural inhibitor of phosphodiesterase 4 (PDE4) with moderate potency and imperfect agent-like properties. Toddacoumalone has the potential for the research of inflammatory diseases such as psoriasis.

HY-12887

Piclamilast RP 73401; RPR 73401	Phosphodiesterase (PDE)	Cancer Inflammation/Immunology
Piclamilast (RP 73401) is a **phosphodiesterase 4 (PDE4) inhibitor, with IC₅₀** values of 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively.

HY-B1639

Enoximone	Phosphodiesterase (PDE)	Inflammation/Immunology Cardiovascular Disease
Enoximone is an inotropic vasodilating agent and a selective and orally active **phosphodiesterase III (PDE3) inhibitor with an IC₅₀** of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits *PDE4* inhibitory effect with an IC₅₀ of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects.

HY-136637

NPD-001	Phosphodiesterase (PDE) Parasite	Infection
NPD-001 is a potent Trypanosoma brucei phosphodiesterases TbrPDEB1 and TbrPDEB2 inhibitor, with IC₅₀ values of 4 and 3 nM, respectively. NPD-001 also inhibits human PDEs (phosphodiesterases). NPD-001 shows good anti trypanosomal activity, with an IC₅₀ of 80 nM.

HY-15025AS

Sildenafil citrate-d8 UK-92480 citrate-d₈	Phosphodiesterase (PDE) Apoptosis Bacterial Autophagy
Sildenafil (citrate)-d₈ is the deuterium labeled Sildenafil citrate[1]. Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM.

HY-14841

Gisadenafil UK-369003	Phosphodiesterase (PDE)	Neurological Disease
Gisadenafil (UK-369003) is a specific, orally active **phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀** of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP).

HY-108045

Lodenafil carbonate	Phosphodiesterase (PDE)	Endocrinology
Lodenafil carbonate, a dimer that acts as a proagent delivering Lodenafil in vivo, is an orally active **phosphodiesterase type 5 (PDE5)** inhibitor for the treatment of erectile dysfunction (ED).

HY-100530B

Sp-cAMPS	PKA Phosphodiesterase (PDE)	Metabolic Disease Neurological Disease
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive **phosphodiesterase (PDE3A) inhibitor with a K_i** of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-100530C

Sp-cAMPS sodium salt	PKA Phosphodiesterase (PDE)	Metabolic Disease Neurological Disease
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive **phosphodiesterase (PDE3A) inhibitor with a K_i** of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-108621

RS-25344 hydrochloride	Phosphodiesterase (PDE)	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
RS-25344 hydrochloride is a selective *cAMP-phosphodiesterase* 4 (PDE 4; PDE IV) inhibitor with an IC₅₀** of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC₅₀ of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects.

HY-U00179

CDC801	Phosphodiesterase (PDE) TNF Receptor	Cancer
CDC801 is a potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-α (TNF-α) inhibitor with IC₅₀ of 1.1 μM and 2.5 μM, respectively.

HY-100650

Carbodenafil	Phosphodiesterase (PDE)	Others
Carbodenafil is a Sildenafil (UK-92480) related compound found in health foods. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.

HY-128593

TPN171	Phosphodiesterase (PDE)	Cardiovascular Disease
TPN171 is a potent, selective and oral bioavailable inhibitor of **phosphodiesterase type 5 (PDE5) with an IC₅₀** of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH).

HY-15025S

Sildenafil-d3 UK-92480-d₃	Phosphodiesterase (PDE)	Cancer Cardiovascular Disease
Sildenafil-d₃ is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.

HY-117109

Amino Tadalafil	Phosphodiesterase (PDE)	Metabolic Disease
Amino Tadalafil is an analog of Tadalafil. Tadalafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with applications in several conditions, including erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract dysfunction.

HY-108619

Gisadenafil besylate UK 369003-26	Phosphodiesterase (PDE)	Neurological Disease
Gisadenafil besylate (UK 369003-26) is a specific, orally active **phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀** of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP).

HY-100933

MY-5445	Phosphodiesterase (PDE)	Cancer Inflammation/Immunology Cardiovascular Disease
MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, **phosphodiesterase type 5 (PDE5), with a K_i of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2**, with anti-proliferative effect.

HY-110005

Sp-cAMPS triethylamine	PKA Phosphodiesterase (PDE)	Metabolic Disease Neurological Disease
Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive **phosphodiesterase (PDE3A) inhibitor with a K_i** of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-119708

Ensifentrine RPL-554	Phosphodiesterase (PDE)	Inflammation/Immunology
Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of **phosphodiesterase 3 (PDE3) and PDE4 with IC₅₀**s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities. Ensifentrine can be used for chronic obstructive pulmonary disease (COPD) research.

HY-116808

TPN729	Phosphodiesterase (PDE)	Neurological Disease
TPN729 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ value of 2.28 nM. TPN729 affects erectile function and it can be used for the research of erectile dysfunction.

HY-15025S1

Sildenafil-d8 UK-92480-d₈	Phosphodiesterase (PDE) Autophagy Apoptosis	Cardiovascular Disease Cancer
Sildenafil-d₈ is the deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM[1][2].

HY-145320

TMX-4113	Phosphodiesterase (PDE) Casein Kinase Molecular Glues	Cancer
TMX-4113 is a degrader of phosphodiesterase 6D (PDE6D) and casein kinase 1α (CK1α). TMX-4113 can be used for the research of cancer.

HY-18253

Udenafil DA8159	Phosphodiesterase (PDE)	Endocrinology Others
Udenafil (DA8159) is a potent, selective and orally active **phosphodiesterase type 5 (PDE5)** inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research.

HY-136569

DSR-141562	Phosphodiesterase (PDE)	Neurological Disease
DSR-141562 is a novel, orally active, and selective brain-penetrant **phosphodiesterase 1 (PDE1)** inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC₅₀ of 43.9 nM, and the IC₅₀ values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia.

HY-128879

VP3.15	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).

HY-128879A

VP3.15 dihydrobromide 1 Publications Verification	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).

HY-108617

YM976	Phosphodiesterase (PDE)	Inflammation/Immunology
YM976 is a phosphodiesterase 4 (PDE4) inhibitor with an IC₅₀ of 2.2 nM. YM976 shows the dissociation of anti-inflammatory activities from emetic effects and inhibits the antigen-induced airway responses.

HY-108623

Atizoram CP-80,633	Phosphodiesterase (PDE)	Inflammation/Immunology
Atizoram (CP-80,633), a cyclic nucleotide phosphodiesterase (PDE4) inhibitor, elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice.

HY-B0140

Aminophylline	Phosphodiesterase (PDE) Adenosine Receptor	Inflammation/Immunology Cancer
Aminophylline is a competitive and non-selective **phosphodiesterase (PDE) inhibitor. Aminophylline is a competitive adenosine receptor** antagonist. Aminophylline has apulmonary vasodilator action as well as a bronchodilator action and has the potential for asthma research.

HY-145321

TMX-4100	Phosphodiesterase (PDE) Molecular Glues	Cancer
TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC₅₀ values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma.

HY-116808B

TPN729MA TPN729 maleate	Phosphodiesterase (PDE)	Neurological Disease
TPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction.

HY-153168

Bemoradan	Phosphodiesterase (PDE)	Cardiovascular Disease
Bemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart failure research.

HY-135490

Reproterol	Adrenergic Receptor Phosphodiesterase (PDE)	Inflammation/Immunology
Reproterol is a dual acting β2-adrenoceptor agonist and *PDE* inhibitor. The theophylline constituent of Reproterol inhibits phosphodiesterase activity induced by adenylyl cyclase. Reproterol has the potential for asthma research.

HY-N8092

Kushenol B	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
Kushenol B is an isoprenoid flavonoid isolated from S. flavescens, has antimicrobial, anti-inflammatory and antioxidant activities. Kushenol B has inhibitory activity against cAMP phosphodiesterase (PDE), with an IC₅₀ of 31 µM.

HY-108620

CDP-840 GR259653X	Phosphodiesterase (PDE)	Inflammation/Immunology
CDP-840 (GR259653X) is a potent, selective and orally active phosphodiesterase IV (PDE IV) inhibitor. CDP-840 inhibits antigen-induced early and late phase bronchoconstriction in conscious squirrel monkeys.

HY-132821B

(R)-Irsenontrine (R)-E2027	Phosphodiesterase (PDE)	Neurological Disease
(R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine (HY-132821), is a potent **phosphodiesterase 9 (PDE9) inhibitor with an IC₅₀** value of 0.041 μM. (R)-Irsenontrine can be used for the research of neurological diseases.

HY-121162

Mesembrine (+)-Mesembrine	5-HT Receptor Phosphodiesterase (PDE)	Neurological Disease
Mesembrine ((+)-Mesembrine) a main alkaloid that features an aryloctahydroindole skeleton. Mesembrine is a 5-HT transporter inhibitor with a K_i of 1.4 nM. Mesembrine also inhibits **phosphodiesterase 4B (PDE4B) with an IC₅₀** of 7.8 μM.

HY-147263

Dovramilast CC-11050	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 *(PDE4)* inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB).

HY-18740A

Trequinsin hydrochloride HL 725	Phosphodiesterase (PDE)	Metabolic Disease
Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of platelet CAMP **phosphodiesterase (PDE), with an IC₅₀** of 0.25 nM. Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine.

HY-117605S

N-Desmethyl Sildenafil-d8 Desmethylsildenafil-d₈; UK-103,320-d₈	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Cancer Neurological Disease
N-Desmethyl Sildenafil-d₈ is the deuterium labeled N-Desmethyl Sildenafil (HY-117605). N-Desmethyl Sildenafil is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor[1][2][3].

HY-100164

SDZ-MKS 492 MKS 492	Phosphodiesterase (PDE)	Inflammation/Immunology
SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited **phosphodiesterase (type III PDE)**. SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats.

HY-B0392

(S)-(+)-Rolipram (+)-Rolipram; (S)-Rolipram	Phosphodiesterase (PDE) Apoptosis	Cancer Inflammation/Immunology Neurological Disease
(S)-(+)-Rolipram ((+)-Rolipram) is a cyclic AMP(cAMP)-specific **phosphodiesterase 4 (PDE4) inhibitor, with an IC₅₀** of 1100 nM. (S)-(+)-Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells.

HY-N10156

1,3,5-Trihydroxy-4-prenylxanthone	Na+/H+ Exchanger (NHE) Phosphodiesterase (PDE) NO Synthase	Inflammation/Immunology
1,3,5-Trihydroxy-4-prenylxanthone is a Na⁺/H⁺ exchange system (Na+/H+ Exchanger (NHE)) inhibitor with a minimum inhibitory concentration of 10 μg/mL. 1,3,5-Trihydroxy-4-prenylxanthone is a **phosphodiesterase type 5 (PDE5) (Phosphodiesterase (PDE)) inhibitor with an IC₅₀ value of 3.0 μM. 1,3,5-Trihydroxy-4-prenylxanthone inhibits Lipopolysaccharide (LPS) (Lipopolysaccharides (HY-D1056)**)-induced NO production in RAW264.7 macrophages, and has anti-inflammatory activities.

HY-N3464

Isopedicin	Phosphodiesterase (PDE)	Metabolic Disease
Isopedicin potently and concentration-dependently inhibits superoxide anion (O2 U?) production in formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)-activated cells. Isopedicin increases cAMP formation and PKA activity in FMLP-activated cells by inhibiting phosphodiesterase (PDE) activity.

HY-B0764A

Bucladesine calcium 20+ Cited Publications Dibutyryl cAMP calcium salt; DBcAMP calcium salt	PKA Phosphodiesterase (PDE) Apoptosis	Others
Bucladesine calcium salt (Dibutyryl-cAMP calcium salt;DC2797 calcium salt) is a cell-permeable cyclic AMP (cAMP) analog and selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine calcium salt acts as a phosphodiesterase (PDE) inhibitor.

HY-N6256

Ilexsaponin B2	Phosphodiesterase (PDE)	Cardiovascular Disease
Ilexsaponin B2 is a saponin isolated from the root of Ilex pubescens Hook. et Arn. Ilexsaponin B2 is a potent **phosphodiesterase 5 (PDE5) and PDEI inhibitor with IC₅₀** values of 48.8 μM and 477.5 μM, respectively.

HY-120577

BA 41899	Others	Cardiovascular Disease
BA 41899 is a purely calcium-sensitizing agent. BA 41899 is completely devoid of phosphodiesterase (PDE) III inhibitory activity or any other known inotropic mechanism. BA 41899 can be used for the research of cardiovascular diseases, such as congestive heart failure (CHF).

HY-15025S2

Sildenafil-d3-1 UK-92480-d₃N_-1	Phosphodiesterase (PDE)	Cancer
Sildenafil-d3-1 (UK-92480-d3-1) is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent **phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀** of 5.22 nM.

HY-18253S

Udenafil-d7	Phosphodiesterase (PDE)	Endocrinology Others
Udenafil-d₇ is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research[1][2].

HY-111673

8-CPT-Cyclic AMP sodium 8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase *(PDE* VA) with an IC₅₀** of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC₅₀Epac and is a potent Epac activator.

HY-108974

Drotaverine hydrochloride	Phosphodiesterase (PDE) Calcium Channel
Drotaverine (hydrochloride) is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects.

HY-133712

Yonkenafil Tunodafil	Phosphodiesterase (PDE)	Neurological Disease
Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.

HY-B0549A

Flavoxate hydrochloride Rec-7-0040; DW61	Phosphodiesterase (PDE) Calcium Channel mAChR	Neurological Disease
Flavoxate hydrochloride is a potent and competitive **phosphodiesterase (PDE) inhibitor. Flavoxate hydrochloride is an antispasmodic agent and muscarinic mAChR antagonist. Flavoxate hydrochloride shows moderate calcium** antagonistic activity and local anesthetic effect. Flavoxate hydrochloride can be used for the research of overactive bladder (OAB) and lower urinary tract infections.

HY-125095

Yonkenafil hydrochloride Tunodafil hydrochloride	Phosphodiesterase (PDE)	Neurological Disease Cardiovascular Disease
Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.

HY-B0549

Flavoxate Rec-7-0040 free base; DW61 free base	Phosphodiesterase (PDE) Calcium Channel mAChR	Neurological Disease
Flavoxate is a potent and competitive **phosphodiesterase (PDE) inhibitor. Flavoxate is an antispasmodic agent and muscarinic mAChR antagonist. Flavoxate shows moderate calcium** antagonistic activity and local anesthetic effect. Flavoxate can be used for the research of overactive bladder (OAB) and lower urinary tract infections.

HY-15297

Vesnarinone 1 Publications Verification OPC-8212	Phosphodiesterase (PDE)	Infection Cardiovascular Disease
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research.

HY-B0764

Bucladesine sodium 20+ Cited Publications Dibutyryl cAMP sodium salt; DBcAMP sodium salt	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a **phosphodiesterase (PDE)** inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing.

HY-107909

Theophylline sodium glycinate 1,3-Dimethylxanthine sodium glycinate; Theo-24 sodium glycinate	Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent **phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC)** activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

HY-12318G

IBMX 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Phosphodiesterase (PDE)	Inflammation/Immunology
IBMX (3-Isobutyl-1-methylxanthine) (GMP) is IBMX (HY-12318) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor.

HY-B0715

Pentoxifylline 5+ Cited Publications BL-191; PTX; Oxpentifylline	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective **phosphodiesterase (PDE)** inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation.

HY-18078

PQ-10	Phosphodiesterase (PDE)	Neurological Disease
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC₅₀ andED₅₀ of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia.

HY-145319

FPFT-2216	Phosphodiesterase (PDE) Casein Kinase Molecular Glues	Cancer Inflammation/Immunology
FPFT-2216, a “molecular glue” compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease.

HY-19026

Siguazodan SKF 94836	Phosphodiesterase (PDE)	Cardiovascular Disease
Siguazodan (SKF 94836) is a potent, selective and orally active **phosphodiesterase III (PDE-III) inhibitor with an IC₅₀ of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC₅₀ of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC₅₀** value of 4.2 μM.

HY-108974S

Drotaverine-d10 hydrochloride	Phosphodiesterase (PDE) Calcium Channel
Drotaverine-d₁₀ (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects[1][2].

HY-135746

OR-1896 1 Publications Verification	Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis	Cardiovascular Disease
OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K⁺ channels and has Ca²⁺-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation.

HY-14930A

Mirodenafil dihydrochloride SK-3530 dihydrochloride	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis	Endocrinology Inflammation/Immunology Neurological Disease
Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective **phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin** signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).

HY-14930

Mirodenafil SK3530	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis	Endocrinology Inflammation/Immunology Neurological Disease
Mirodenafil (SK3530) is an orally active, potent, reversible, and selective **phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin** signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).

HY-B0763

Ibudilast 4 Publications Verification KC-404; AV-411; MN-166	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.

HY-B0809A

Theophylline monohydrate 1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Cancer
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent **phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC)** activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

HY-B0809

Theophylline 5 Publications Verification 1,3-Dimethylxanthine; Theo-24	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Cancer
Theophylline (1,3-Dimethylxanthine) is a potent **phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC)** activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent **phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC)** activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

HY-N2284

Sophoflavescenol	Cholinesterase (ChE) Beta-secretase Phosphodiesterase (PDE)	Cancer
Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC₅₀ of 0.013 μM against **Phosphodiesterase 5 (PDE5)**, and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC₅₀s of 0.30 µM, 0.17 µM, 17.89 µg/mL, 10.98 µM, 8.37 µM and 8.21 µM, respectively.

HY-13295

Vinpocetine 5+ Cited Publications Ethyl apovincaminate	Sodium Channel IKK Phosphodiesterase (PDE)	Inflammation/Immunology Neurological Disease Cardiovascular Disease Cancer
Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na⁺ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a **phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK)**, and has been widely used for the treatment of cerebrovascular disorders.

HY-B1816

Zaprinast M&B 22948	Phosphodiesterase (PDE) GPR35	Neurological Disease Cardiovascular Disease Endocrinology
Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective **Phosphodiesterase (PDE5). Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 (GPR35)** agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects.

HY-B0715S

Pentoxifylline-d6 BL-191-d₆; PTX-d₆; Oxpentifylline-d₆	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0715S2

Pentoxifylline-d5 BL-191-d₅; PTX-d₅; Oxpentifylline-d₅	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0763S1

Ibudilast-d7	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Ibudilast-d₇ is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[1].

HY-B0763S2

Ibudilast-d7-1 KC-404-d₇-1; AV-411-d₇-1; MN-166-d₇-1	Phosphodiesterase (PDE)
Ibudilast-d₇-1 is the deuterium labeled Ibudilast[1]. Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[2].

HY-100936

Etazolate hydrochloride SQ 20009; EHT 0202 hydrochloride	Phosphodiesterase (PDE) GABA Receptor	Inflammation/Immunology Neurological Disease
Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC₅₀ of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABA_A) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects.

HY-13295S

Vinpocetine-d5	Sodium Channel IKK Phosphodiesterase (PDE)	Inflammation/Immunology Neurological Disease Cardiovascular Disease Cancer
Vinpocetine-d₅ is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders[1][2][3].

HY-101762

TyK2-IN-2	JAK Phosphodiesterase (PDE)	Inflammation/Immunology
TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC₅₀s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TyK2-IN-2 also inhibits **phosphodiesterase 4 (PDE4) with an IC₅₀** of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases.

HY-N3945

Glaucine O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396	Phosphodiesterase (PDE) Calcium Channel Adrenergic Receptor Dopamine Receptor Influenza Virus	Infection Inflammation/Immunology
Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active **phosphodiesterase 4 (PDE4) inhibitor with K_is of 3.4 µM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca²⁺ entry blocker, and a weak dopamine D1 and D2 receptor** antagonist. Glaucine has antioxidative and antiviral activities.

Cat. No.	Product Name	Type

Cat. No.	Product Name	Target	Research Area

Cat. No.	Product Name	Target	Category

Species:	Human (8) Mouse (1)
Tag:	His (8) Tag Free (1) Myc (1) GST (4)
Source:	Sf9 insect cells (5) E. coli (4)

Cat. No.	Product Name	Species	Source

Cat. No.	Product Name